IQVIA Notes Increasing Share Of Deals Between Smaller Biopharmas

 
• By Joseph Haas

In its 2023 report on global R&D trends for the biopharma sector, IQVIA found a shrinking percentage of deals involving $5bn+ revenue companies; R&D spending among big pharmas is the highest since 2014.

Business trend
Deals between smaller companies are a bigger share of overall biopharma business development • Source: Shutterstock

More from Strategy

More from Business